How to buy ImmunoPrecise Antibodies (IPA) stock

ImmunoPrecise Antibodies Ltd is a biotechnology business based in the US. ImmunoPrecise Antibodies shares (IPA) are listed on the NASDAQ and all prices are listed in US Dollars.

ImmunoPrecise Antibodies stock price (NASDAQ: IPA)

Use our graph to track the performance of IPA stocks over time.

ImmunoPrecise Antibodies shares at a glance

• Key figures

Information last updated 2021-07-23.

Latest market close	$7.82
52-week range	$1.00 - $33.34
50-day moving average	$6.31
200-day moving average	$10.48
Wall St. target price	N/A
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	N/A

Buy ImmunoPrecise Antibodies shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy ImmunoPrecise Antibodies stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of ImmunoPrecise Antibodies Ltd by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

ImmunoPrecise Antibodies price performance over time

Historical closes compared with the close of $7.82 from 2021-05-28

1 week (2021-07-15)	N/A
1 month (2021-06-25)	21.43%
3 months (2021-04-26)	-17.34%
6 months (2021-01-22)	N/A

1 year (2020-07-22)	N/A
2 years (2019-07-22)	N/A
3 years (2018-07-22)	N/A
5 years (2016-07-22)	N/A

ImmunoPrecise Antibodies financials

Revenue TTM	$17.2 million
Gross profit TTM	$8 million
Return on assets TTM	-9.68%
Return on equity TTM	-13.93%
Profit margin	-18.94%
Book value	$1.88
Market capitalisation	$252.2 million

TTM: trailing 12 months

Shorting ImmunoPrecise Antibodies shares

There are currently 146,987 ImmunoPrecise Antibodies shares held short by investors – that's known as ImmunoPrecise Antibodies's "short interest". This figure is 18.2% up from 124,385 last month.

There are a few different ways that this level of interest in shorting ImmunoPrecise Antibodies shares can be evaluated.

ImmunoPrecise Antibodies's "short interest ratio" (SIR)

ImmunoPrecise Antibodies's "short interest ratio" (SIR) is the quantity of ImmunoPrecise Antibodies shares currently shorted divided by the average quantity of ImmunoPrecise Antibodies shares traded daily (recently around 51938.869257951). ImmunoPrecise Antibodies's SIR currently stands at 2.83. In other words for every 100,000 ImmunoPrecise Antibodies shares traded daily on the market, roughly 2830 shares are currently held short.

To gain some more context, you can compare ImmunoPrecise Antibodies's short interest ratio against those of similar companies.

• Amgen (AMGN.US): 3.8
• Regeneron Pharmaceuticals (REGN.US): 1.71
• Biogen (BIIB.US): 0.53

However ImmunoPrecise Antibodies's short interest can also be evaluated against the total number of ImmunoPrecise Antibodies shares, or, against the total number of tradable ImmunoPrecise Antibodies shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case ImmunoPrecise Antibodies's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 ImmunoPrecise Antibodies shares in existence, roughly 10 shares are currently held short) or 0.0086% of the tradable shares (for every 100,000 tradable ImmunoPrecise Antibodies shares, roughly 9 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against ImmunoPrecise Antibodies.

Find out more about how you can short ImmunoPrecise Antibodies stock.

ImmunoPrecise Antibodies share dividends

We're not expecting ImmunoPrecise Antibodies to pay a dividend over the next 12 months.

You may also wish to consider:

• Amgen (AMGN.US) (2.68% forward annual dividend yield)

Have ImmunoPrecise Antibodies's shares ever split?

ImmunoPrecise Antibodies's shares were split on a 4:1 basis on 29 May 2013. So if you had owned 1 share the day before before the split, the next day you'd have owned 4 shares. This wouldn't directly have changed the overall worth of your ImmunoPrecise Antibodies shares – just the quantity. However, indirectly, the new 75% lower share price could have impacted the market appetite for ImmunoPrecise Antibodies shares which in turn could have impacted ImmunoPrecise Antibodies's share price.

ImmunoPrecise Antibodies share price volatility

Over the last 12 months, ImmunoPrecise Antibodies's shares have ranged in value from as little as $1 up to $33.34. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ImmunoPrecise Antibodies's is -0.2368. This would suggest that ImmunoPrecise Antibodies's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, ImmunoPrecise Antibodies has bucked the trend.

To put ImmunoPrecise Antibodies's beta into context you can compare it against those of similar companies.

• Amgen (AMGN.US): 0.71
• Regeneron Pharmaceuticals (REGN.US): 0.185
• Biogen (BIIB.US): 0.4227

ImmunoPrecise Antibodies overview

ImmunoPrecise Antibodies Ltd. , together with its subsidiaries, engages in the antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune and naive phage display production and screening; hybridoma production with screening and clone-picking; transgenic animals and multi-species antibody discovery; antibody characterization studies, such as affinity measurements, functional assays and epitope mapping, and binning; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA synthesis and cloning, protein and antibody downstream processing; antibody engineering; transient and stable cell line generation; antibody optimization and humanization; and cryopreservation. The company has collaboration with Eurofins Discovery to develop antibody discovery platform. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada.

Frequently asked questions

What percentage of ImmunoPrecise Antibodies is owned by insiders or institutions?
Currently 6.727% of ImmunoPrecise Antibodies shares are held by insiders and 7.208% by institutions. When does the fiscal year end for ImmunoPrecise Antibodies?
ImmunoPrecise Antibodies's fiscal year ends in April. Where is ImmunoPrecise Antibodies based?
ImmunoPrecise Antibodies's address is: 3204?4464 Markham Street, Victoria, BC, Canada, V8Z 7X8